Navigation Links
New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
Date:5/14/2009

Analysis indicates that one life is now saved for every six patients who receive an ICD

NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that an analysis of long-term data from the MADIT II clinical study demonstrates that the life-saving benefits of implantable cardioverter defibrillator (ICD) therapy remain sustainable at eight years. This is the first time long-term data have been presented regarding the life-saving benefits of ICDs in a primary prevention population. The analysis was presented during a late-breaking session at the Heart Rhythm Society Scientific Sessions in Boston.

The analysis shows a sustainable mortality benefit over time, including:

  • At eight years, one life is saved for every six patients who receive an ICD. This represents a significant improvement over the two-year MADIT II data, which showed one life saved for every 17 patients.
  • A 41 percent relative reduction in the risk of death for ICD patients at four years
  • A 37 percent relative reduction in the risk of death for ICD patients at eight years

The MADIT II study, sponsored exclusively by Boston Scientific, was designed to determine whether ICDs improve survival when compared to drug therapy alone in heart attack survivors with moderate impairment of the left ventricle, the heart's main pumping chamber. Initial results published in the New England Journal of Medicine (March 21, 2002) demonstrated that ICD therapy reduced the relative risk of death by 31 percent at 20 months follow-up.

"ICD therapy has proved effective in patients at risk of sudden cardiac death, and now the long-term MADIT II data show the life-saving benefits of these devices continue over tim
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
(Date:10/28/2014)... 27, 2014)—Although oral hormonal therapy is known to ... hormone receptor–positive tumors, about one-half of patients fail ... by Columbia University Medical Center (CUMC) researchers has ... (the most common type of hormone therapy), which ... increased treatment adherence by 50 percent. , The ...
(Date:10/27/2014)... for informal caregiving of elderly people by friends and ... a year, according to a new RAND Corporation study. ... minimum wage would cost $221 billion, while replacing ... annually. , The study, published online by the ... the value of informal caregiving by making use of ...
(Date:10/27/2014)... adopt a new therapy by watching others use it, ... , New technology is like an influential colleague -- ... reminded every five to seven days , CHICAGO ... when they are persuaded to do so by an influential ... adopting innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 CALNOC, ... announced its annual CALNOC Performance Excellence Awards recognizing ... of reducing hospital acquired pressure ulcers, injuries from ... their commitment and dedication to nursing quality. , ... and affiliation. These hospitals have a long and ...
Breaking Medicine News(10 mins):Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 2Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 4
... life hangs between life and death, suffering an extremely rare ... transplant, which will give him a new lease of life. ... will be donating a kidney each. , ,Mrs ... felt so helpless, especially as you're used to doing everything ...
... confirmed that the bird flu virus found in poultry in ... to humans as well //. ,As chief veterinarian ... laboratory that it was the highly pathogenic H5N1 strain of ... ,This is the first report of the H5N1 virus in ...
... Hospital's two pediatricians, Jo McCubbin and Peter Goss have ... months notice //. However a full time replacement ... ,This has led to concerns among obstetricians at ... obstetricians would not be able to deliver premature babies ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... Ramadoss Friday warned of "strong action" against "indiscipline" he ... of Medical Sciences// (AIIMS), saying a coterie had turned ... people have converted the AIIMS into a political hub ... return to New Delhi June 19," Ramadoss told reporters ...
... the Karolinska Institutet they have found ways to control the ... intestinal stem cell. The result of the study was published ... help in the development of new drugs for diseases such ... body, old cells are continually being replaced by new. If ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Mechanism of Stem Cell Regulation Identified 2
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus sweatband....
Medicine Products: